Reduction of cardiovascular risk and mortality: A population-based approach

Advances in Therapy

Volumn 23, Issue 6, 2006, Pages 905-920

  Casiglia, Edoardo ^a   Saugo, Mario ^b   Schiavon, Laura ^a   Tikhonoff, Valérie ^a   Rigoni, Giulio ^c   Basso, Giancarlo ^b   Mazza, Alberto ^a   Rizzato, Enzo ^d   Guglielmi, Francesco ^a,b   Martini, Bortolo ^b   Bascelli, Anna ^a,b   Caffi, Sandro ^b   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Hospital of Schio Thiene   (Italy)

^c Center of Epidemiology and Biostatistics   (Italy)

^d Hospital of Rovigo   (Italy)

Author keywords

Cardiovascular risk; Cholesterol; Diabetes; Epidemiology; Hypertension; Mortality

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; AWARENESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLECYSTOKININ BLOOD LEVEL; EVALUATION; FATALITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; ITALY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MORTALITY; PHYSICIAN ATTITUDE; POPULATION RESEARCH; REFUSAL TO PARTICIPATE; RISK ASSESSMENT; RISK REDUCTION; STROKE;

AGED; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC STUDIES; FEMALE; HEALTH EDUCATION; HUMANS; HYPERTENSION; LIFE STYLE; MALE; RISK FACTORS;

EID: 33847376807     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850213     Document Type: Article

References (44)

1. Casiglia E, Mazza A, Tikhonoff V, Pessina AC. Population-based studies improve outcome in hypertensive patients. Am J Hypertens. 2002;15:605-608.
2. Casiglia E, Basso G, Guglielmi F, et al. German origin clusters for high cardiovascular risk in an Italian enclave. Int Heart J. 2005;46:489-500.
3. Casiglia E, Mazza A, Tikhonoff V, et al. Protocol and experimental design of the LEOGRA (Last Evidences Of Genetic Risk factors in the Aged) study, a population-based genetic approach to cardiovascular risk. J Hypertens. 2000;18(suppl 2):174.
4. Casiglia E, Palatini P. Cardiovascular risk factors in the elderly. J Hum Hypertens. 1998;12:575-581.
5. Kannel WC. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging. 2003;20:186-277.
6. Kamel N, Gursoy A, Koseoglulari O, Dincer I, Gullu S. Isolated office hypertension: association with target organ damage and cardiovascular risk indices. J Nat Med Assoc. 2006;98:601-606.
7. Fagard CH, Staessen JA, Thjis L. Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Curr Opin Cardiol. 2001;16:342-348.
8. Cheng S, Lichtman JH, Amatruda JM, et al. Knowledge of blood pressure levels and targets in patients with coronary artery disease in the USA. J Hum Hypertens. 2005;19:769-774.
9. Joffres MR, Hamet P, MacLean DR, L'Italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099-1105.
10. Cruickishank JK, Mbanya JC, Wilks R, et al. Hypertension in four African-origin populations: current 'rules of halves,' quality of blood pressure control and attributable risk of cardiovascular disease. J Hypertens. 2001;19:41-46.
11. Pan WH, Chang HY, Yeh WT, et al. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan 1993-1996. J Hum Hypertens. 2001;15:793-798.
12. Bonegas J, Rodrigues-Artalejo E, Ruilope M, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157-2164.
13. Casiglia E, Mazza A, Tikhonoff V, et al. Weak effects of hypertension and other classic risk factors in the elderly who have already paid their toll. J Human Hypertens. 2002;16:21-31.
14. Pessina AC, Casiglia E. Are hypertensive patients undertreated? Aging Health. 2005;1:355-357.
15. Celis H, Fagard R, Staessen JA, Thijs L. Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe trial. Curr Opin Cardiol. 2001;16;342-348.
16. Jiles R, Hughes E, Murphy W, et al. Surveillance for certain health behaviors among states and selected local areas; behavioral risk factor surveillance system, United States, 2003. MMWR-CDC Surveill Summ 2005;54:1-116. Available at: http://www.cdc.gov/mmvr/preview/mmwrhtml/ss5408a1.htm
17. Arnett DK, Jacobs DR, Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002, Circulation. 2005;112:3884-3891.
18. Muntner P, Gu D, Reynolds RF, et al. Therapeutic lifestyle changes and drug treatment for high blood cholesterol in China and application of the Adult Treatment Panel III guidelines. Am J Cardiol. 2005;96:1260-1265,
19. Mancia G. Total cardiovascular risk: new treatment concept. J Hypertens. 2006;24;S17-S24.
20. Dal Palú C, Magnani B, Zanchetti A, et al. Structured approach to the treatment of hypertension: Italian project. Cardiovasc Prev. 1995;4:141-153.
21. Di Bari M, Salti F, Nardi M, et al. Undertreatment of hypertension in community-dwelling older adults: a drug-utilization study in Dicomano, Italy. J Hypertens. 1999;17:1633-1640.
22. Prencipe M, Casini AR, Santini M, Ferretti C, Scaldaferri N, Culasso F. Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J Hum Hypertens. 2000;14:825-830.
23. Amery A, Birkenhager W, Brixko P, et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party of High Blood Pressure in the Elderly. J Hypertens. 1985;3:s501-s511.
24. Amery A, Birkenhager W, Brixko P, et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet. 1986;2:589-592.
25. Dahlof B, Lindholm LH, Hansson L, Schersten B, Egbon T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
26. Sutton-Tyrrell K, Alcorn HG, Herzog H, Keesley SF, Kuller LH. Morbidity, mortality and antihypertensive treatment effects by extent of arteriosclerosis in older adults with isolated systolic hypertension. Stroke. 1995;26:1319-1324.
27. Ong HT. The statin studies: from targeting hypercholesterolemia to targeting the high-risk patient. Q J Med. 2005;90:599-614.
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
29. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
30. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
31. Shepherd J, Blauw GJ, Murphy MB, et al, for the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
32. Samuelsson OG, Vilhemsen LW, Svardsudd KF, Pennert KM, Wedel H, Berglund GL. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: the Study of Men Born in 1913 and the Multifactorial Primary Prevention Trial. J Hypertens. 1987;5:57-66.
33. Langford HG. Reduced stroke incidence in HDFP enhanced by strong support system. Am Heart J. 1982;103:1087-1088.
34. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872.
35. McVeigh GE, Flack J, Grimm R: Goals of antihypertensive therapy. Drugs. 1995;49:161-175.
36. Julius S. Five decades of antihypertensive treatment: the unresolved issues. J Hypertens. 2000;18(suppl):S3-S7.
37. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol And Recurrent Events (CARE) Trial Investigators. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1995;333:1301-1307.
38. Ravnskov U, Rosch PJ, Sutter MC. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
39. Wanner C, Krane V, Marz W, et al, for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
40. Lemos PA, de Feyter PJ, Serruys PW, et al. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. Int J Cardiol. 2005;98:479-486.
41. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart. 2006;92:1402-1408.
42. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in the clinical practice: the Brisighella Heart Study. J Hypertens. 2004;22:1707-1718.
43. Menotti A, Lanti M, Zanchetti A, et al. Impact of the Gubbio Population Study on community control of blood pressure and hypertension. J Hypertens. 2001;19:843-850.
44. Casiglia E, Tikhonoff V, Mazza A, Pessina AC. Systolic and pulse hypertension. Aging Health. 2005;1:85-94.